SEC Form 4/A · accession 0001209191-16-141544
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jeffrey S Glenn
Director
Period of report
Mar 28, 2016
Accepted (ET)
Sep 15, 2016 · 2:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $15.75 | Mar 28, 2016 | A | 25,000 | A | — | Mar 28, 2026 | Common Stock | 25,000 | 25,000 | D |
| Stock Option (Right to Buy)F2,F3 | $15.75 | Mar 28, 2016 | A | 30,000 | A | — | Mar 28, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date.
- F2The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016.
- F3The option vests in equal monthly installments over 36 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date.